In:
Biotechnology and Applied Biochemistry, Wiley, Vol. 69, No. 5 ( 2022-10), p. 2112-2121
Abstract:
One of the major complications of diabetes is diabetic nephropathy, and often many patients suffer from diabetic nephropathy. That is why it is important to find the mechanisms that cause nephropathy and its treatment. This study was designed to examine the antidiabetic effects of biochanin A (BCA) and evaluate its effects on oxidative stress markers and the expression of transforming growth factor‐β1 (TGF‐β1) and protease‐activated receptors‐2 (PAR‐2) genes in the kidney of type 1 diabetic rats. After induction of diabetes using streptozotocin (STZ), 55 mg/kg bw dose, rats were randomly divided into four groups with six rats in each group as follows: normal group: normal control receiving normal saline and a single dose of citrate buffer daily; diabetic control group: diabetic control receiving 0.5% dimethyl sulfoxide daily; diabetic+BCA (10 mg/kg) group: diabetic rats receiving biochanin A at a dose of 10 mg/kg bw daily; diabetic+BCA (15 mg/kg) group: diabetic rats receiving biochanin A at a dose of 15 mg/kg bw daily. TGF‐β1 and PAR‐2 gene expression was assessed by real‐time. Spectrophotometric methods were used to measure biochemical factors: fast blood glucose (FBG), urea, creatinine, albumin, lipids profiles malondialdehyde (MDA), and superoxide dismutase (SOD). The course of treatment in this study was 42 days. The results showed that in the diabetic control group, FBG, serum urea, creatinine, expression of TGF‐β1 and PAR‐2 genes, and the levels of MDA in kidney tissue significantly increased and SOD activity in kidney tissue and serum albumin significantly decreased compared to the normal group ( p 〈 0.001). The results showed that administration of biochanin A (10 and 15 mg/kg) after 42 days significantly reduced the expression of TGF‐β1 and PAR‐2 genes and FBG, urea, creatinine in serum compared to the diabetic control group ( p 〈 0.001), also significantly increased serum albumin compared to the diabetic control group ( p 〈 0.001). The level of MDA and SOD activity in the tissues of diabetic rats that used biochanin A (10 and 15 mg/kg) was significantly reduced and increased, respectively, compared to the diabetic control group ( p 〈 0.001). Also, the result showed that in the diabetic control group lipids profiles significantly is disturbed compared to the normal group ( p 〈 0.001), the results also showed that biochanin A (10 and 15 mg/kg) administration could significantly improved the lipids profile compared to the control diabetic group ( p 〈 0.001). It is noteworthy that it was found that the beneficial effects of the biochanin A were dose dependent. In conclusion, administration of biochanin A for 42 days has beneficial effect and improves diabetes and nephropathy in diabetic rats. So probably biochanin A can be used as an adjunct therapy in the treatment of diabetes.
Type of Medium:
Online Resource
ISSN:
0885-4513
,
1470-8744
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
1496341-3
SSG:
12
Bookmarklink
